[ad_1]
Basel
Roche can achieve successful results in treating corona pneumonia with one product and announces a new antibody test.
Roche is advancing its search for a crown drug. Roche’s drug Actemra / RoActemra (tocilizumab), which has already been approved, achieved the desired effect in patients with corona-related pneumonia in the phase III study EMPACTA.
Patients who received Actemra / RoActemra plus standard treatment were 44 percent less likely to be hooked up to the ventilator or to die compared to those who received placebo plus standard treatment. The Basel pharmaceutical giant announced this on Friday.
New antibody test
Roche will also launch an antibody test that can be used to identify people who have been infected with the coronavirus and who have already developed antibodies. The test could play an important role in characterizing a vaccine-induced immune response, Roche said. After all, most of the current vaccine candidates aim to trigger an antibody reaction against the spike protein in the coronavirus.
The test will be introduced in countries that accept the EU CE mark. An emergency approval (EUA) has been requested from the US health authority FDA.
